MacroGenics (MGNX) Crashed 28% After Pausing Phase 2 TAMARACK Study, Class Action Accuses Company of Misleading Investors Over Cancer Drug Trial

SAN FRANCISCO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now. Class Period: Mar. 7, 2024 – May 9, 2024 Lead Plaintiff Deadline: Sept. 24, 2024 Visit: www.hbsslaw.com/investor-fraud/mgnx Contact the Firm Now: MGNX@hbsslaw.com 844-916-0895 Class Action Lawsuit Against MacroGenics, Inc. (MGNX): On July 30, 2024, shares in beleaguered pharmaceutical company MacroGenics crashed after the company provided ...